KR930009607A - 증식성 질환의 치료를 위한 다이피리다몰 - Google Patents

증식성 질환의 치료를 위한 다이피리다몰 Download PDF

Info

Publication number
KR930009607A
KR930009607A KR1019920021672A KR920021672A KR930009607A KR 930009607 A KR930009607 A KR 930009607A KR 1019920021672 A KR1019920021672 A KR 1019920021672A KR 920021672 A KR920021672 A KR 920021672A KR 930009607 A KR930009607 A KR 930009607A
Authority
KR
South Korea
Prior art keywords
dipyridamole
administration
use according
cell proliferation
treatment
Prior art date
Application number
KR1019920021672A
Other languages
English (en)
Inventor
프란시스 카프만 레이몬드
팔 신 자이
Original Assignee
리로이 휘테커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리로이 휘테커, 일라이 릴리 앤드 캄파니 filed Critical 리로이 휘테커
Publication of KR930009607A publication Critical patent/KR930009607A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

억제량의 다이피리다몰을 국소 투여하는 것을 포함하는, 포유동물에서 세포 증식을 억제하는 방법이 개시된다. 세포증식의 억제를 혈관성 재발협착증, 공피증, 건선 및 류마티스관절염 등과 같은 증식성 질환의 치료에 유용하다. 본 발명은 국소 투여 카테터, 부위 특이적 담체, 이식편, 직접 주사 또는 직접 적용등의 다양한 투여기법에 의해 증식부위에 다이피리다몰을 국소 투여하는 방법이다.

Description

증식성 질환의 치료를 위한 다이피리다몰
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 증식 부위에 직접 다이피리다몰을 투여함으로써 세포 증식을 비-전신적 방법으로 치료하기 위한 다이피리다몰의 용도.
  2. 증식성 혈관 평활근 세포에 직접 다이피리다몰을 투여함으로써 혈관 평활근 세포 증식을 비-전신적 방법으로 치료하기 위한 다이피리다몰의 용도.
  3. 제2항에 있어서, 국소 투여용 카테터를 사용하여 투여하는 용도.
  4. 제2항에 있어서, 부위 특이적 담체를 사용하여 투여하는 용도.
  5. 제2항에 있어서, 이식편을 사용하여 투여하는 용도.
  6. 제2항에 있어서, 막고정 링커를 사용하여 투여하는 용도.
  7. 제2항에 있어서, 직접 주사에 의해 투여하는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920021672A 1991-11-21 1992-11-18 증식성 질환의 치료를 위한 다이피리다몰 KR930009607A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/795,434 1991-11-21
US07/795,434 US5270047A (en) 1991-11-21 1991-11-21 Local delivery of dipyridamole for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
KR930009607A true KR930009607A (ko) 1993-06-21

Family

ID=25165502

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920021672A KR930009607A (ko) 1991-11-21 1992-11-18 증식성 질환의 치료를 위한 다이피리다몰

Country Status (12)

Country Link
US (2) US5270047A (ko)
EP (1) EP0543653A1 (ko)
JP (1) JPH05201862A (ko)
KR (1) KR930009607A (ko)
AU (1) AU661067B2 (ko)
CA (1) CA2083223A1 (ko)
HU (1) HU212422B (ko)
MX (1) MX9206610A (ko)
NO (1) NO924461L (ko)
RU (1) RU2084224C1 (ko)
TW (1) TW252917B (ko)
ZA (1) ZA928832B (ko)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994016706A1 (en) * 1993-01-28 1994-08-04 Neorx Corporation Therapeutic inhibitors of vascular smooth muscle cells
JPH08510451A (ja) * 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
DE69435342D1 (de) * 1993-07-19 2011-05-05 Angiotech Pharm Inc Anti-Angiogene Mittel und Verfahren zu deren Verwendung
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5521191A (en) * 1994-10-17 1996-05-28 Washington University Method for treatment of arterial stenosis
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US7896914B2 (en) * 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US7846202B2 (en) 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
CA2178541C (en) * 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US7867275B2 (en) * 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
AU6277396A (en) 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US7550005B2 (en) * 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US20070203520A1 (en) * 1995-06-07 2007-08-30 Dennis Griffin Endovascular filter
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5951586A (en) * 1996-05-15 1999-09-14 Medtronic, Inc. Intraluminal stent
DK0914102T3 (da) 1996-05-24 2006-01-09 Angiotech Pharm Inc Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US6530951B1 (en) 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6569688B2 (en) 1997-08-26 2003-05-27 Technion Research & Development Foundation Ltd. Intravascular apparatus method
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) * 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
JP4898991B2 (ja) 1998-08-20 2012-03-21 クック メディカル テクノロジーズ エルエルシー 被覆付植込式医療装置
US6168619B1 (en) * 1998-10-16 2001-01-02 Quanam Medical Corporation Intravascular stent having a coaxial polymer member and end sleeves
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
ATE460951T1 (de) * 2000-01-25 2010-04-15 Edwards Lifesciences Corp Freisetzungssysteme zur behandlung von restenose und anastomotischer intimaler hyperplasie
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
ES2243556T3 (es) 2000-10-16 2005-12-01 Conor Medsystems, Inc. Dispositivo medico expandible para proporcionar un agente beneficioso.
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20040073294A1 (en) * 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US6964680B2 (en) * 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US7064130B2 (en) 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
DE10119680A1 (de) * 2001-04-20 2002-11-14 Boehringer Ingelheim Pharma Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
EP1448205B1 (en) 2001-10-05 2011-03-23 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
US20030077310A1 (en) * 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US20030083614A1 (en) * 2001-10-30 2003-05-01 Boehringer Ingelheim Pharma Kg Controlled release endoprosthetic device
EP1308179A1 (en) * 2001-10-30 2003-05-07 Boehringer Ingelheim Pharma GmbH & Co.KG Improved endoprosthetic device
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
MXPA04006875A (es) * 2002-01-18 2004-12-06 Control Delivery Sys Inc Sistema de gel polimerico para suministro controlado de cofarmacos.
US10441747B2 (en) 2002-01-22 2019-10-15 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
AU2003205315A1 (en) * 2002-01-22 2003-09-02 Endobionics, Inc. Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
US7744584B2 (en) 2002-01-22 2010-06-29 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
EP1521603B1 (en) * 2002-07-12 2011-01-19 Cook Incorporated Coated medical device
US20040127976A1 (en) * 2002-09-20 2004-07-01 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US20040162542A1 (en) * 2002-12-03 2004-08-19 Endobionics, Inc. Methods and systems for treating the vasculature with estrogens
CN1747734A (zh) * 2003-02-07 2006-03-15 贝林格尔·英格海姆国际有限公司 潘生丁或单哌潘生丁在治疗和预防mmp-9-依赖性疾病中的用途
WO2004087214A1 (en) 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device with beneficial agent concentration gradient
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2007139753A2 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
WO2009038708A1 (en) * 2007-09-19 2009-03-26 Combinatorx, Incorporated Therapeutic regimens for the treatment of immunoinflammatory disorders
CN101938996A (zh) * 2007-12-17 2011-01-05 康宾纳特克斯公司 用于治疗免疫炎症性紊乱的治疗方案
CA3035774A1 (en) 2016-09-22 2018-03-29 Mercator Medsystems, Inc. Treatment of restenosis using temsirolimus
CN110996687A (zh) 2017-05-26 2020-04-10 墨卡托医疗系统公司 用于治疗再狭窄的联合疗法
CN110382019B (zh) 2018-03-14 2020-08-25 墨卡托医疗系统公司 用于局部药物递送的医疗器械和医疗方法
WO2021077070A1 (en) * 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies
CN113244395B (zh) * 2020-02-10 2024-07-23 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
CA1208516A (en) * 1982-04-02 1986-07-29 Harvey Wolinsky Methods and apparatus for relieving arterial constrictions
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
AU4191989A (en) * 1988-08-24 1990-03-23 Marvin J. Slepian Biodegradable polymeric endoluminal sealing
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
DE69023362T2 (de) * 1989-01-31 1996-04-04 Bard Inc C R Katheter und Methode zur lokal angewandten Medikation der Wand eines Blutgefässes oder eines anderen Körperlumens.
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors

Also Published As

Publication number Publication date
HU9203626D0 (en) 1993-01-28
US5314688A (en) 1994-05-24
HU212422B (en) 1996-06-28
HUT70034A (en) 1995-09-28
JPH05201862A (ja) 1993-08-10
MX9206610A (es) 1993-05-01
ZA928832B (en) 1994-05-16
AU2845492A (en) 1993-05-27
AU661067B2 (en) 1995-07-13
NO924461D0 (no) 1992-11-19
EP0543653A1 (en) 1993-05-26
RU2084224C1 (ru) 1997-07-20
CA2083223A1 (en) 1993-05-22
TW252917B (ko) 1995-08-01
NO924461L (no) 1993-05-24
US5270047A (en) 1993-12-14

Similar Documents

Publication Publication Date Title
KR930009607A (ko) 증식성 질환의 치료를 위한 다이피리다몰
RU92004406A (ru) Дипиридамол для лечения пролиферативных болезней
FI943805A (fi) Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
DE69833942D1 (de) Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
ATE221881T1 (de) Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat
ATE202140T1 (de) Hemmung der neovaskulasierung durch vegf- spezifische oligonukleotide
ATE407573T1 (de) Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion
NO991685D0 (no) Anvendelse av 1-benzyl-3-(substituert hetaryl)-kondenserte pyrazolderivater for behandling av spesielle sykdommer i hjerte-kretsl°psystemet og sentralnervesystemet
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
ES2147780T3 (es) Compuestos sinteticos afines al extracto de corteza de roble, y procedimiento para utilizar los mismos.
DE69526853D1 (de) Hemmung der fortpflanzung von arterienglattmuskelzellen
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
DE69201660D1 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
ATE526944T1 (de) Selbstbräunungszusammensetzungen die cholesterolsulfat und dha enthalten
ES2061811T3 (es) Uso de compuestos de gamma-oxibutenolido conjugados para tratar ulcera.
ES2171419T3 (es) Uso de los inhibidores del citocromo p450 para inhibir el metabolismo del nitrogeno sustituido acridina.
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
ATE245991T1 (de) Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin
DE69218200D1 (de) Behandlung von leberkrebs
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid